Will you be attending SLAS2024 in Boston? This year the programme will feature a track curated by DDW taking place in the Ignite Theater ‘Innovation & technology: from lab to patient’.
Co-sponsored by Integra Biosciences and Hamamatsu Corporation, the Ignite Theater will be live on 5 and 6 February 2024 in the SLAS2024 exhibition hall.
On Tuesday 6 February at 11.30am, the speaker will be Masaru Kanekiyo, DVM, PhD, Investigator and Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH.
Kanekiyo is a vaccine immunologist with an interest in structure-based vaccine design, viral immunity and host-pathogen interplay, and will discuss ‘Structural vaccinology for influenza: The technology behind the NIAD VRC’s nanoparticle-based vaccines.’
What you will learn:
- The mechanisms behind structure-based vaccine design
- The role of computational protein design in vaccine immunogen discovery
- How new technology is enabling quicker and more comprehensive characterisation of vaccine candidates
DDW asked him about the role of technology in vaccine development. “Technology plays multiple roles in all stages of vaccine development,” Kanekiyo said. “It is enabling computational protein design for vaccine immunogen discovery, and high-throughput and high-definition assays for quicker and more comprehensive characterisation of vaccine candidates and vaccine-elicited immunity. In the future, machine learning, especially prediction and generation of new structures, might become an essential tool and play a big role in vaccine and drug discovery.”